ValuEngine upgraded shares of Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) from a buy rating to a strong-buy rating in a research report sent to investors on Tuesday.
Shares of Opiant Pharmaceuticals (OPNT) opened at 36.00 on Tuesday. The company’s 50-day moving average is $23.82 and its 200 day moving average is $11.27. The company has a market capitalization of $72.94 million, a price-to-earnings ratio of 13.54 and a beta of -0.75. Opiant Pharmaceuticals has a 12 month low of $5.00 and a 12 month high of $51.90.
Opiant Pharmaceuticals (NASDAQ:OPNT) last issued its quarterly earnings results on Wednesday, June 14th. The technology company reported ($1.55) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.82) by ($0.73). Opiant Pharmaceuticals had a return on equity of 5,686.82% and a net margin of 38.89%. The business had revenue of $0.02 million during the quarter. On average, equities research analysts anticipate that Opiant Pharmaceuticals will post $0.50 earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: “Opiant Pharmaceuticals, Inc. (OPNT) Upgraded to Strong-Buy at ValuEngine” was originally posted by Markets Daily and is owned by of Markets Daily. If you are accessing this piece of content on another site, it was copied illegally and republished in violation of United States & international copyright laws. The legal version of this piece of content can be read at https://www.themarketsdaily.com/2017/09/13/opiant-pharmaceuticals-inc-opnt-upgraded-to-strong-buy-at-valuengine.html.
Opiant Pharmaceuticals Company Profile
Opiant Pharmaceuticals, Inc, formerly Lightlake Therapeutics, Inc, is a specialty pharmaceutical company. The Company develops pharmacological treatments for substance use, addictive and eating disorders. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdoses, which was conceived, licensed, developed and approved by the United States Food and Drug Administration (FDA).
Receive News & Ratings for Opiant Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.